Physician profile
Mayada Ismail
NPI 1740663962
$2,936.98
in general payments reported to CMS, 2019-2025
13 companies · $1,366 in 2025
The $1,366 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $112 · 2021: $55.37 · 2022: $28.31 · 2023: $538 · 2024: $146 · 2025: $1,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,036 · Travel and Lodging: $1,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,036.15 |
| Travel and Lodging | $1,013.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,182.84 | 2024-2025 | General - Therapies, Apollo Esg System, Overstitch Endoscopic Suturing System |
| Apollo Endosurgery US INC | $538.08 | 2023 | Overstitch Endoscopic Suturing System |
| Takeda Pharmaceuticals U.S.A., INC. | $399.14 | 2019-2021 | |
| Abbvie INC. | $349.29 | 2019-2024 | |
| Novo Nordisk INC | $156.00 | 2025 | |
| Medtronic, INC. | $94.34 | 2024 | Gi Genius |
| Fujifilm Healthcare Americas Corporation | $62.35 | 2025 | |
| Shionogi INC | $34.17 | 2019 | |
| Braintree Laboratories, INC. | $32.78 | 2019 | |
| Merck Sharp & Dohme LLC | $28.71 | 2019-2020 | |
| Pfizer INC. | $25.28 | 2019-2020 | |
| Janssen Biotech, INC. | $18.12 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayada Ismail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.